Company intelligence / Profile preview
AnaptysBio, Inc.
San Diego/Carlsbad*, California, United States of Americaanaptysbio.gcs-web.com ↗
- Ownership
- Public · ANAB
- Employees
- ~136
- Development stage
- Phase 2
01
Overview
AnaptysBio is a clinical-stage biotechnology company specializing in immune cell-modulating antibodies for autoimmune and inflammatory diseases. Its pipeline includes multiple mid-stage assets such as Rosnilimab and ANB032 in Phase 2 trials, with Imsidolimab advancing into late-stage development for generalized pustular psoriasis. The company leverages its proprietary SHM-XEL platform for rapid antibody discovery and optimization. It has established royalty revenue streams from partnered programs like Jemperli with GSK and continues to expand through strategic licensing agreements.[1][2][4][5]
- Therapeutic areas
- GastroenterologyImmunologyDermatology
- Modalities
- Monoclonal antibodies (mAbs)Immune cell modulatorsCytokine antagonists[2][4][5][6]
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
GlaxoSmithKline plc. (“GSK”) – collaboration/license agreement for Jemperli royaltiesVanda Pharmaceuticals – contract for imsidolimab development/commercializationCentessa Pharmaceuticals – exclusive license agreement for BDCA2 modulator programSagard Healthcare Royalty Partners – monetization of future royalties/milestones.[2]
04
Financials
- Market cap
- $1.6B
- Total revenue
- $25.6M
- Enterprise value
- $1.6B
Beyond the preview
Go deeper on AnaptysBio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AnaptysBio, Inc..